Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3174359 | 0.91 | HRH3 (0.43) | HRH3CHRNA7CDK6CCNT1CDK1 | |
| SCHEMBL3167033 | 0.90 | HRH3 (0.43) | HRH3CHRNA7CDK6CCNT1CDK1 | |
| SCHEMBL3537168 | 0.89 | HRH3 (0.55) | HRH3CHRNA7CDK6CCNT1CDK9 | |
| SCHEMBL3174819 | 0.89 | HRH3 (0.42) | HRH3CHRNA7CDK6CCNT1CDK1 | |
| SCHEMBL3160492 | 0.89 | CHRNA7 (0.46) | HRH3CHRNA7 | |
| SCHEMBL3539521 | 0.89 | HRH3 (0.42) | HRH3CHRNA7CDK6CCNT1CDK1 | |
| SCHEMBL3160029 | 0.88 | HRH3 (0.45) | HRH3CHRNA7CCNT1CDK9 | |
| SCHEMBL3165604 | 0.87 | RAB9A (0.49) | HRH3 | |
| SCHEMBL3174684 | 0.87 | HRH3 (0.41) | HRH3CHRNA7CDK6CCNT1CDK1 | |
| SCHEMBL3160440 | 0.86 | HRH3 (0.43) | HRH3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7648979-B2 | 5-amido-(1H-indol-2-yl)-piperazin-1-yl-methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-01-19 | — | — | US | disclosed |
| EP-2118059-A1 | 5 -AMIDO- (IH- INDOL- 2 -YL) PIPERAZIN-1-YL-METHANONE DERIVATIVES AS HISTAMINE H3 RECEPTOR LIGANDS | F. Hoffmann-Roche AG (CH) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008095823-A1 | 5 -AMIDO- (IH- INDOL- 2 -YL) PIPERAZIN-1-YL-METHANONE DERIVATIVES AS HISTAMINE H3 RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-14 | — | — | WO | disclosed |
| US-20080188487-A1 | 5-AMIDO-(1H-INDOL-2-YL)-PIPERAZIN-1-YL-METHANONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188487-A1 | 5-AMIDO-(1H-INDOL-2-YL)-PIPERAZIN-1-YL-METHANONE DERIVATIVES | HRH4, HRH3, HRH2 | HRH3 2/4885CHRNA7 129/4885CDK6 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.